Related Experiment Video

Updated: Jul 4, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

[How I treat... by optimizing the blockade of the renin-angiotensin-aldosterone system]

F Schleich1, J M Krzesinski, L Piérard

  • 1Université de Liège, Belgique.

Revue Medicale De Liege
|June 26, 2008
PubMed

Insights

Optimizing the blockade of the renin-angiotensin-aldosterone system (RAAS) is crucial for managing cardiovascular and kidney diseases. This involves using maximal monotherapy dosages or dual RAAS inhibition for enhanced cardiorenal protection.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Pharmacology

Context:

  • The renin-angiotensin-aldosterone system (RAAS) plays a critical role in cardiovascular and renal homeostasis.
  • Dysregulation of RAAS is implicated in arterial hypertension, heart failure, post-myocardial infarction complications, and nephropathy.
  • Current RAAS blockade strategies include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors like aliskiren.

Purpose:

  • To review and describe methods for optimizing RAAS blockade.
  • To highlight the benefits of enhanced RAAS blockade for cardiorenal protection.
  • To explore novel strategies and future directions in RAAS inhibition therapy.

Summary:

  • Optimizing RAAS blockade is essential for managing various cardiovascular and renal conditions.
  • Strategies include maximizing monotherapy doses or employing dual RAAS inhibition (e.g., ACE inhibitor + ARB, or ARB + aliskiren).
  • These optimized approaches aim to provide superior cardiorenal protection compared to standard therapies.

Impact:

  • Improved patient outcomes in hypertension, heart failure, and chronic kidney disease.
  • Enhanced cardiorenal protection through optimized pharmacological interventions.
  • Potential for new therapeutic strategies in managing RAAS-mediated diseases.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...